Alzheimer's Diagnosis Paradigm Shift: From Biomarkers to Cognitive Decline

A proposed revision to Alzheimer's diagnostic criteria shifts emphasis from amyloid/tau biomarkers alone to cognitive and functional impairment as the disease's defining feature. This aligns diagnosis with clinical reality and enables earlier intervention.

Why Change?

• Biomarker-clinical mismatch: 30% of cognitively normal elders have amyloid plaques; some with dementia have minimal plaques.
• Earlier detection: Functional decline precedes dementia diagnosis by years.
• Treatment relevance: Emerging therapies (anti-amyloid) work best early; need diagnostic framework for pre-dementia stages.
• Patient-centeredness: Focus on lived experience, not just pathology.

Proposed Three-Stage Framework

Stage	Biomarkers	Cognition/Function	Clinical Label
1. Preclinical	Abnormal (amyloid/tau/neurodegeneration)	Normal	Asymptomatic at risk
2. Mild Cognitive Impairment (MCI)	Abnormal	Mild decline, independence preserved	Prodromal AD
3. Dementia	Abnormal	Significant impairment in daily activities	Alzheimer's dementia

Implications

• Research: Enrich clinical trials with earlier-stage participants.
• Clinical: Diagnose and treat MCI due to AD; monitor preclinical if desired.
• Insurance/Policy: Coverage for early interventions, care planning.
• Public perception: Reduce fatalism; emphasize actionable window.

Challenges

• Biomarker access/standardization (PET, CSF, blood tests).
• Overdiagnosis anxiety in preclinical stage.
• Equity: ensuring diverse populations benefit.

This shift reflects a maturing field: Alzheimer's is a clinical-biological continuum, not a binary pathology.